Spinal Decompression Plus Nerve Graft Implantation Following TSCI
Eligible age
18–80 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This is a single-blinded (with outcome assessors blinded to treatment allocation), 12-month pilot study to evaluate of the safety, feasibility, and preliminary efficacy of dorsal myelotomy and expansive duraplasty performed either without or with autologous nerve graft implantation after acute traumatic spinal cord injury. Ten participants will be allocated to receive either DMED (n=5) or DMED + ANGI (n=5) based on a block design. Participants and assessors will be blinded to group allocation. Excess sural nerve samples will be collected for banking/analysis (may include proteomic, culturing, genomic, cellular analysis).
Sponsor: Francis Farhadi
You may qualify if…
- ✓ Age: = 18 years and = 80 years
- ✓ Written informed consent by patient or legal authorized representative
- ✓ No other life-threatening injury
- ✓ No evidence of sepsis
- ✓ Acute cervical or thoracic SCI with ASIA Impairment Scale grade A or B on admission
- ✓ Non-penetrating SCI at neurologic level from C2 to C8 or T1 to T12
- ✓ The ability to undergo surgical intervention including study procedures through a posterior approach within 48 hours of injury
You may not qualify if…
- ✕ Unconsciousness or other mental impairment that prevents neurological assessment within the first 48 hours
- ✕ Acute SCI with ASIA Impairment Scale grade C, D or E
- ✕ Spinal cord decompression and spinal stabilization can be safely performed through an anterior-only approach (i.e. posterior approach is not required)
- ✕ Currently involved in another non-observational SCI research study or receiving another investigational drug
- ✕ Other illness (including mental disorder) that could preclude accurate medical and neurological evaluation (at discretion of the principal investigator)
- ✕ Unable to commit to the follow-up schedule
- ✕ A recent history of regular substance abuse (illicit drugs, alcohol), which in the opinion of the investigator would interfere with the subject's participation in the study
- ✕ Any condition likely to result in the patient's death within the next 12 months
Where it's recruiting
Lexington
Source: ClinicalTrials.gov · NCT06243211 · last updated 2025-12-10